Skip to main content

Ontario, New Entrant To Join Opioid Class Action

Ontario, New Entrant To Join Opioid Class Action

Ontario, New Entrant To Join Opioid Class Action

Introduction

On Wednesday, Ontario passed a bill to join five other provinces in a class-action suit led by British Columbia against opioid manufacturers alleging false marketing tactics.

The suit is filed in a bid to recoup costs from manufacturers and distributors for the nuances caused post its introduction in 1996 into the Canadian market. The province stated that they would invest the potential settlement amount into front-line mental health and addiction services. Other provinces who support the lawsuit include New Brunswick, Newfoundland, and Labrador, Saskatchewan, and Alberta.

A study by a national advisory committee shows around 14,000 Canadians have been killed by the opioid over the last four years. The number is high in the U.S, with 400,000 deaths between 1999 and 2017.

More than 2,600 lawsuits are consolidated under MDL No. 2804 (In Re: National Prescription Opiate Litigation) presided by U.S. District Judge Dan Polster.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!